Chronic kidney disease and non-alcoholic fatty liver disease - new pathogenetic links
https://doi.org/10.31146/1682-8658-ecg-212-4-140-144
Abstract
This article discusses the association between non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD). There is ample evidence of an increased risk of CKD in patients with NAFLD. Most researchers attribute to the common risk factors for these two conditions. Currently, in addition to traditional factors associated with CKD and NAFLD, such as components of the metabolic syndrome, the influence of new pathogenetic factors, i. e. endothelial dysfunction, metabolic disorders of fibroblast growth factor-21, pathological activation of the renin-angiotensin system and influence of adiponectin level change are considered. Further examination of these mechanisms will open up new therapeutic options for the treatment of CKD and NAFLD.
About the Authors
Ya. A. Krasner
Novosibirsk State Medical University
Russian Federation
Russian Federation
M. F. Osipenko
Novosibirsk State Medical University
Russian Federation
Russian Federation
S. I. Holin
Novosibirsk State Medical University
Russian Federation
Russian Federation
N. V. Litvinova
Novosibirsk State Medical University
Russian Federation
Russian Federation
References
1. Carney E. F. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020 May;16(5):251. doi: 10.1038/s41581-020-0268-7.
2. Liu Y., Zhong G. C., Tan H. Y., Hao F. B., Hu J. J. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Scientific Reports. 2019 Jul 31;9(1):11124. doi: 10.1038/s41598-019-47687-3.
3. Byrne C.D., Targher G. NAFLD: A multisystem disease. J. Hepatol. 2015 Apr;62(1 Suppl): S47-64. doi: 10.1016/j.jhep.2014.12.012.
4. Bakulin I.G., Sandler Yu.G., Vinnitskaya E. V., Keian V. A., Rodionova S. V., Rotin D. L. Sakharnyi diabet i nealkogol’naya zhirovaya bolezn’ pecheni: grani sopryazhennosti [Diabetes mellitus and nonalcoholic fatty liver disease: The verges of contingency]. Ter Arkh. 2017;89(2):59-65.Russian. doi: 10.17116/terarkh201789259-65.
5. Byrne C.D., Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020 Apr;72(4):785-801. doi: 10.1016/j.jhep.2020.01.013.
6. Targher G., Bertolini L., Rodella S., Lippi G., Zoppini G., Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010 Dec;5(12):2166-71. doi: 10.2215/CJN.05050610.
7. Musso G., Gambino R., Tabibian J. H., Ekstedt M., Kechagias S., Hamaguchi M. et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014 Jul 22;11(7): e1001680. doi: 10.1371/journal.pmed.1001680.
8. Park H., Dawwas G. K., Liu X., Nguyen M. H.Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: A propensity-matched cohort study. J Intern Med. 2019 Dec;286(6):711-722. doi: 10.1111/joim.12964.
9. Vilar-Gomez E., Calzadilla-Bertot L., Friedman S. L., Gra-Oramas B., Gonzalez-Fabian L., Villa-Jimenez O. et al. Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2017 Jan;45(2):332-344. doi: 10.1111/apt.13860.
10. Cao Y., Deng Y., Wang J., Zhao H., Zhang J., Xie W. The association between NAFLD and risk of chronic kidney disease: a cross-sectional study. Ther Adv Chronic Dis. 2021 Nov 9;12:20406223211048649. doi: 10.1177/20406223211048649.
11. Moody W.E., Edwards N. C., Madhani M. et al. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis. 2012 Jul;223(1):86-94. doi: 10.1016/j.atherosclerosis.2012.01.043.
12. Kurapova M. V., Nizyamova A. R., Romasheva E. P., Davydkin I. L. Endothelial dysfunction in patients with chronic kidney disease. Proceedings of the Samara Scientific Center of the Russian Academy of Sciences. 2013;15(3):1823-1826. (in Russ.)@@ Курапова М. В., Низямова А. Р., Ромашева Е. П., Давыдкин И. Л. Эндотелиальная дисфункция у больных хронической болезнь почек. Известия Самарского научного центра Российской академии наук. 2013, Том 15, N 3, С. 1823-1826.
13. Xin Z., Liu S., Niu J., Xu M., Wang T., Lu J. et al. The association of low-grade albuminuria with incident non-alcoholic fatty liver disease and non-invasive markers of liver fibrosis by glycaemia status. Liver Int. 2021 Jan;41(1):101-109. doi: 10.1111/liv.14649.
14. Al-Hamoudi W., Alsadoon A., Hassanian M., Alkhalidi H., Abdo A., Nour M. et al. Endothelial dysfunction in nonalcoholic steatohepatitis with low cardiac disease risk. Sci Rep. 2020 Jun 1;10(1):8825. doi: 10.1038/s41598-020-65835-y.
15. Jose N., Vasant P. K., Kuliranka K. G. Study of Endothelial Dysfunction in Patients With Non-alcoholic Fatty Liver Disease. Cureus. 2021 Dec 19;13(12): e20515. doi: 10.7759/cureus.20515.
16. Khukhlina O.S., Antoniv A. V., Mandryk O. Ye., Smandych V. S., Matushchak M. R. The role of endothelial dysfunction in the progression mechanisms of non-alcoholic steatohepatitis in patients with obesity and chronic kidney disease. Wiad Lek. 2019;72(4):523-526. PMID: 31055525.
17. Musso G., Cassader M., Cohney S., Pinach S., Saba F., Gambino R. Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends Mol. Med. 2015 Oct;21(10):645-662. doi: 10.1016/j.molmed.2015.08.005.
18. Triozzi J., Richardson P. A., Parker Gregg L., Navaneethan S. D. Incidence and predictors of non-alcoholic fatty liver disease among patients with chronic kidney disease. Nephrol Dial Transplant. 2021 Jul 23;36(8):1546-1548. doi: 10.1093/ndt/gfab046.
19. Bataller R., Sancho-Bru P., Ginès P., Lora J. M., Al-Garawi A., Solé M. et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003 Jul;125(1):117-25. doi: 10.1016/s0016-5085(03)00695-4.
20. Kohara M., Masuda T., Shiizaki K., Akimoto T., Watanabe Y., Honma S. et al. Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLoS One. 2017 Jun 5;12(6): e0178971. doi: 10.1371/journal.pone.0178971.
21. Zhang C., Shao M., Yang H., Chen L., Yu L., Cong W. et al. Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation. PLoS One. 2013 Dec 9;8(12): e82275. doi: 10.1371/journal.pone.0082275.
22. Markan K. R. Defining “FGF21 Resistance” during obesity: Controversy, criteria and unresolved questions. F1000Res. 2018 Mar 7;7:289. doi: 10.12688/f1000research.14117.1.
23. Hui E. Y. L., Woo Y. C., Yeung C. Y., Chow W. S., Yuen M. M. A. et al. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. J. Clin. Endocrinol. Metab. 2015 Apr;100(4):1368-75. doi: 10.1210/jc.2014-3465.
24. Proshchai G.A., Vorokhobina N. V., Zagarskikh E. Y., Partsernyak S. A., Partsernyak A. S. Fibroblast growth factor 21 and its influence on metabolic processes in the human body. Vestnik of Saint Petersburg University. Medicine. 2018;13(1):38-45. (in Russ.) doi: 10.21638/11701/spbu11.2018.104.@@ Прощай Г. А., Ворохобина Н. В., Загарских Е. Ю., Парцерняк С. А., Парцерняк А. С. Фактор роста фибробластов 21 и его влияние на метаболические процессы в организме человека. Вестник Санкт-Петербургского университета, 2018, Т. 13, Вып. 1, С. 38-42. doi: 10.21638/11701/spbu11.2018.104.
25. Tucker B., Li H., Long X., Rye K. A., Ong K. L. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism. 2019 Dec;101:153994. doi: 10.1016/j.metabol.2019.153994.
26. Ohashi K., Ouchi N., Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie. 2012 Oct;94(10):2137-42. doi: 10.1016/j.biochi.2012.06.008.
27. Zoccali C., Postorino M., Marino C., Pizzini P., Cutrupi S., Tripepi G. Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. Journal of internal medicine. 2011 Feb;269(2):172-81. doi: 10.1111/j.1365-2796.2010.02288.x.
28. Spranger J., Kroke A., Mohlig M., Bergmann M. M., Ristow M., Boeing H., Pfeiffer A. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003 Jan 18;361(9353):226-8. doi: 10.1016/S0140-6736(03)12255-6. Erratum in: Lancet. 2002 Mar 22;361(9362):1060.
29. Musso G., Gambino R., Durazzo M., Biroli G., Carello M., Faga E., Pacini G., De Michieli F., Rabbione L., Premoli A., Cassader M., Pagano G.: Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology. 2005 Nov;42(5):1175-83. doi: 10.1002/hep.20896.
30. Przybyciński J., Dziedziejko V., Puchałowicz K., Domański L., Pawlik A. Adiponectin in Chronic Kidney Disease.International Journal of Molecular Sciences. 2020 Dec 9;21(24):9375. doi: 10.3390/ijms21249375.
31. Kuo I.C., Wu P. H., Lin H. Y., Niu S. W., Huang J. C., Hung C. C., Chiu Y. W., Chen H. C. The association of adiponectin with metabolic syndrome and clinical outcome in patients with non-diabetic chronic kidney disease. PLoS One. 2019 Jul 19;14(7): e0220158. doi: 10.1371/journal.pone.0220158.
32. Ix J.H., Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 2010 Mar;21(3):406-12. doi: 10.1681/ASN.2009080820.
Review
For citations:
Krasner Ya.A., Osipenko M.F., Holin S.I., Litvinova N.V. Chronic kidney disease and non-alcoholic fatty liver disease - new pathogenetic links. Experimental and Clinical Gastroenterology. 2023;(4):140-144. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-212-4-140-144
Views:
826
Email this article 